Albireo to Present New Data at the 54th Annual Meeting of ESPGHAN
– Four abstracts accepted of Phase 3 data from PEDFIC 1 and PEDFIC 2 trials of Bylvay™ (odevixibat) – Three...
News
Longboard Pharmaceuticals to Present at the JMP Securities 2022 Life Sciences Conference on June 15
SAN DIEGO, June 07, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing...
Palisade Bio to Present at the 2022 BIO International Convention
In-person presentation on Monday, June 13th at 1:45 PM PTCARLSBAD, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI),...
Clearmind Medicine Announces Positive Pre-Clinical Results for Cocaine Addiction Treatment
The dedicated treatment demonstrated a significant decrease in preference for an area associated with cocaine VANCOUVER, June 07, 2022 (GLOBE...
Acer Therapeutics Issues Statement Regarding PDUFA Target Action Date for ACER-001
NEWTON, Mass., June 07, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition,...
SciSparc Ltd. Announces Initial Positive Results for the Cocaine Addiction Treatment of Clearmind Medicine Inc.
SciSparc and Clearmind recently announced the filing of a patent application related to treating cocaine addictionTEL AVIV, Israel, June 07,...
Simply Better Brands Corp and Jones Soda Co. Announce Termination of Letter of Intent Due to Unfavourable Market Conditions
VANCOUVER, British Columbia, June 07, 2022 (GLOBE NEWSWIRE) -- Simply Better Brands Corp. ( “Simply Better Brands” or “SBBC”) (TSX...
Pharvaris Participates in the Kinin 2022 Conference
Pharvaris’ tailored drug development approach to enable treatment of people living with all types of hereditary angioedema (HAE) presented at...
Evaxion Biotech Secures Equity Financing of up to $40 Million from Lincoln Park Capital
COPENHAGEN, Denmark, June 07, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology...
Ceapro Announces Results of 2022 Shareholders’ Meeting
EDMONTON, Alberta, June 07, 2022 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage...
Eyenovia Announces Planned Chief Executive Officer Transition
CEO Dr. Sean Ianchulev will transition to non-executive Chairman of the BoardNEW YORK, June 07, 2022 (GLOBE NEWSWIRE) -- Eyenovia,...
Observed Safety Profile Supports Bilateral Dosing of ProKidney’s REACT™ – 007 Update
Potential for Amplified Therapeutic Effect of REACT™ with Bilateral Kidney Injections Potential to report data from enhanced delivery approach 1Q...
ORYZON Awarded EU Seal of Excellence and Public Financing of $2M USD to Develop Iadademstat in Acute Myeloid Leukemia
Non-refundable funds from the Next Generation-EU programMADRID, Spain and CAMBRIDGE, Mass., June 07, 2022 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A....
scPharmaceuticals Inc. Announces Abstracts Accepted for Presentation at the American Association of Heart Failure Nurses 18th Annual Meeting
Oral and moderated poster presentations of FREEDOM-HF study to be presentedBURLINGTON, Mass., June 07, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc....
Enlivex to Present at the 2022 Jefferies Healthcare Conference
Nes-Ziona, Israel, June 07, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting...
Soleno Therapeutics Announces Presentations at ENDO 2022
REDWOOD CITY, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing...
Singular Genomics and Olink Collaborate to Enable Olink® Explore on the G4 Max Read™ Sequencing Kits
Max Read kits on the G4 Sequencing Platform will produce up to 4 billion reads per run, enabling high throughput,...
Jasper Therapeutics to Participate in the William Blair 42nd Annual Growth Stock Conference
REDWOOD CITY, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on enabling...
AUM Biosciences Announces FDA IND Authorization for Global Phase 2 Trial of Selection Translation Inhibitor AUM001 in Colorectal Cancer
SINGAPORE and BETHESDA, Md., June 07, 2022 (GLOBE NEWSWIRE) -- AUM Biosciences, a global clinical-stage biotech company, focused on discovering...
eFFECTOR Therapeutics to Present at JMP Securities Life Sciences Conference
SAN DIEGO and REDWOOD CITY, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a biopharmaceutical company...